Third Rock Rolls
This article was originally published in Start Up
Executive Summary
Founded by a team of former Millennium Pharmaceutical executives including former CEO Mark Levin, Third Rock Ventures intends to return to the venture capital model of old. The Boston-based firm intends to start companies that can leverage a novel technology capable of creating multiple drugs for multiple diseases.
You may also be interested in...
Few Exits, But Lots Of Cash: Third Rock Closes $516M Third Fund
The early-stage biotech venture firm drew its largest fund yet, topping $1 billion raised since inception, despite notching only two exits from its first two funds.
The A-List: 2008's Trend Shaping Series A Financings
Despite a miserable economy, new company formation continues apace. In biotech, recapitalizations and structured deals featured prominently; in diagnostics, interest remains strong even if rounds in 2008 were down from last year's highs; in devices, small and regional VCs have filled the void left by brand-name investors.
The A-List: 2008's Trend Shaping Series A Financings
Despite a miserable economy, new company formation continues apace. In biotech, recapitalizations and structured deals featured prominently; in diagnostics, interest remains strong even if rounds in 2008 were down from last year's highs; in devices, small and regional VCs have filled the void left by brand-name investors.